Entero has signed a binding term sheet in which private biotech Journey is slated to acquire 99% of Entero’s equity, ...
Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback